Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udai Banerji

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigatorsChristophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2008
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer modelsUdai Banerji, Nivedita Sain, Swee Y Sharp, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2018
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trialsTerri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unitKhurum Khan, Joo Ern Ang, Naureen Starling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2018
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trialsAlvaro H Ingles Garces, Joo Ern Ang, Malaka Ameratunga, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2018
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer modelsUdai Banerji, Nivedita Sain, Swee Y Sharp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
Journal of the National Cancer Institute|November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer modelsYuen-Li Chung, Helen Troy, Udai Banerji, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigatorsChristophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2008
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer modelsUdai Banerji, Nivedita Sain, Swee Y Sharp, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2018
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trialsTerri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, et al.
The Lancet. Oncology|February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trialsTimothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unitKhurum Khan, Joo Ern Ang, Naureen Starling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2018
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trialsAlvaro H Ingles Garces, Joo Ern Ang, Malaka Ameratunga, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2018
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer modelsUdai Banerji, Nivedita Sain, Swee Y Sharp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
Journal of the National Cancer Institute|November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer modelsYuen-Li Chung, Helen Troy, Udai Banerji, et al.
Pageof 13